Progression of VEGFR-TKI in advanced non-small cell lung cancer
JIANG Kan
Abstract：Angiogenesis plays an important role in tumor genesis and development.Therefore,anti-angiogenic therapy has become an important part in cancer therapy and throughout the entire therapy process.Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) is small molecular anti-angiogenic drug.This article introduces the domestic and international listed and researching VEGFR-TKIs.The models of single-agent/combined with chemotherapy drugs/combined with targeted drugs can improve the objective response rates (ORR)of advanced non-small cell lung cancer (NSCLC),lengthen progression-free survival(PFS).But it was failed to lengthen overall survival(OS).And the adverse effects of VEGFR-TKIs were greater.How to improve the efficacy and reduce adverse effects will be the direction of future research.
Keywords：Non-small cell lung cancer(NSCLC)Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs)Objective response rates(ORR)Progression-free survival(PFS)Overall survival(OS)
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 845-850 )